CONTENTI supported BD in com­mu­ni­cat­ing drug delivery inno­va­tions that give chronic disease sufferers new autonomy.

Large-molecule mon­o­clon­al anti­bod­ies (mAbs) are trans­form­ing chronic disease therapies but require inno­v­a­tive delivery solutions for safe, effective and com­fort­able home-based care.

Communicating drug delivery inno­va­tion took a number of forms in our work with BD. We wrote numerous articles in the pro­fes­sion­al press, in col­lab­o­ra­tion with BD experts, com­mu­ni­cat­ing solutions designed to meet new drug delivery chal­lenges. These chal­lenges included higher vis­cosi­ties, larger dose volumes, new dose regimens and higher protein con­cen­tra­tions asso­ci­at­ed with novel bio­phar­ma­ceu­ti­cals. 

Campaign elements:

(click to expand)

“Selecting drug delivery systems for higher doses, higher vis­cosi­ties and lower risk”

“Gliding towards derisked com­bi­na­tion product devel­op­ment”

“How shorter needles with thinner walls are set to improve the injection expe­ri­ence in chronic care”

Poster session — content, graphic and editorial support

“Innovating in the high viscosity design space”

“Identifying new, enhanced drug delivery devices for chronic care”